pyrroles has been researched along with darapladib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballantyne, CM; Davidson, MH; Hanefeld, M; Johnson, JL; Mohler, ER; Ruilope, LM; Zalewski, A | 1 |
| Corson, MA | 1 |
1 trial(s) available for pyrroles and darapladib
| Article | Year |
|---|---|
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Benzaldehydes; Biomarkers; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; Male; Middle Aged; Oximes; Prognosis; Pyrroles; Recurrence; Risk Factors | 2008 |
1 other study(ies) available for pyrroles and darapladib
| Article | Year |
|---|---|
Phospholipase A2 inhibitors in atherosclerosis: the race is on.
Topics: Atorvastatin; Benzaldehydes; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oximes; Phospholipases A2, Secretory; Pyrroles | 2009 |